Review
Immunology
Maria Lesniak, Justyna Lipniarska, Patrycja Majka, Weronika Kopyt, Monika Lejman, Joanna Zawitkowska
Summary: Toll-like receptors (TLR7 and TLR8) located in endosomes recognize single-stranded RNA molecules and synthetic DNA/RNA analogs. They play a role in blood cellular component formation and contribute to the pathogenesis of hematopoietic malignancies. TLR agonists have shown positive effects in therapy for hemato-oncological diseases.
Review
Oncology
Giovanni Riva, Vincenzo Nasillo, Anna Maria Ottomano, Giuliano Bergonzini, Ambra Paolini, Fabio Forghieri, Beatrice Lusenti, Patrizia Barozzi, Ivana Lagreca, Stefania Fiorcari, Silvia Martinelli, Rossana Maffei, Roberto Marasca, Leonardo Potenza, Patrizia Comoli, Rossella Manfredini, Enrico Tagliafico, Tommaso Trenti, Mario Luppi
Summary: MRD monitoring plays an increasingly important role in the clinical management of hematologic malignancies, providing valuable information for treatment selection. However, further research is needed to determine the specific prognostic value of MRD in different hematologic settings, as well as its appropriate clinical applications in order to improve standardization and harmonization of MRD monitoring protocols.
Review
Oncology
Aaron Tsumura, Daniel Levis, Joseph M. Tuscano
Summary: Checkpoint inhibitor therapy has shown great efficacy in the treatment of malignancies, particularly in solid tumors and Hodgkin lymphoma. It not only has therapeutic potential in relapsed/refractory hematologic malignancies, but also synergistically enhances the efficacy of other treatment modalities.
FRONTIERS IN ONCOLOGY
(2023)
Review
Immunology
Alessandro Allegra, Alessandro Tonacci, Caterina Musolino, Giovanni Pioggia, Sebastiano Gangemi
Summary: Secondary immunodeficiency is common in patients with hematological malignancies, affecting their risk of infection and overall prognosis. Treatment strategies need to be personalized based on individual clinical and immunological conditions, with potential risks associated with vaccination such as decreased immune response and adverse reactions.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Yongxian Hu, Jingjing Li, Fang Ni, Zhongli Yang, Xiaohua Gui, Zhiwei Bao, Houli Zhao, Guoqing Wei, Yiyun Wang, Mingming Zhang, Ruimin Hong, Linqin Wang, Wenjun Wu, Mohamad Mohty, Arnon Nagler, Alex H. Chang, Marcel R. M. van den Brink, Ming D. Li, He Huang
Summary: This study compares the gut microbiome diversity and composition during different phases of CAR-T therapy and finds that it is associated with patient response to therapy and occurrence of immune-related adverse effects.
NATURE COMMUNICATIONS
(2022)
Review
Hematology
Andrew W. Roberts, Andrew H. Wei, David C. S. Huang
Summary: BH3 mimetics are a new class of anticancer drugs that target prosurvival BCL2 proteins to induce apoptosis, with Venetoclax being the first approved BCL2 inhibitor showing activity in various lymphoid and myeloid neoplasms. Long-term exposure may lead to secondary resistance. Success of BCL2 inhibitors has led to development of BH3 mimetics targeting MCL1, with promising preclinical activity but potential challenges due to MCL1's physiological roles in nonhematologic tissues.
Review
Biochemistry & Molecular Biology
Lu Tang, Zhongpei Huang, Heng Mei, Yu Hu
Summary: The immune-cell origin of hematologic malignancies has contributed to accelerated progress in immunotherapy by providing insights into immune responsiveness and escape mechanisms. Different categories of immunotherapies, such as stem cell transplantation and immune checkpoint inhibitors, have shown potential for long-term remission in blood cancers. However, these approaches also have shortcomings that need to be addressed. A comprehensive review provides clinicians with historical perspectives, recent advances, mechanisms of action, clinical trials and outcomes, adverse effects and toxicity management, as well as challenges and future directions in immunotherapy for hematologic malignancies.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Review
Cell Biology
Laura Gragnani, Serena Lorini, Silvia Marri, Anna Linda Zignego
Summary: Notch receptors play critical roles in fundamental cellular processes and are implicated in hematopoiesis, angiogenesis, and various human malignancies. They could serve as potential therapeutic targets for hematological cancers.
Review
Oncology
Bouthaina Dabaja, Michael Spiotto
Summary: Over the past half-century, the role of radiotherapy has shifted from directly killing cancer cells to stimulating anti-tumor immune responses. This interplay between radiation, the tumor microenvironment, and the immune system is crucial in cancer immunology. While most studies have focused on solid tumors, there is growing understanding of this interaction in hematological malignancies. This review highlights recent advances in immunotherapy and adoptive cell therapy and emphasizes the importance of incorporating radiation therapy into the treatment of hematological malignancies.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Hye Sun Kuehn, Julie E. Niemela, Jennifer Stoddard, Sara Ciullini Mannurita, Tala Shahin, Shubham Goel, Mary Hintermeyer, Raul Jimenez Heredia, Mary Garofalo, Laura Lucas, Smriti Singh, Annalisa Tondo, Zachary Jacobs, William A. Gahl, Sylvain Latour, James Verbsky, John Routes, Charlotte Cunningham-Rundles, Kaan Boztug, Eleonora Gambineri, Thomas A. Fleisher, Shanmuganathan Chandrakasan, Sergio D. Rosenzweig
Summary: IKAROS is a transcription factor involved in lymphocyte development and function. Mutations affecting its C-terminal dimerization domain have been linked to hematologic disorders, disrupting dimerization and altering key gene regulation mechanisms. These mutations contribute to a growing spectrum of IKAROS-associated diseases with a genotype-phenotype correlation.
Article
Oncology
Qianling Ye, Yun Lin, Ruihao Li, Huaiji Wang, Chunyan Dong
Summary: This article introduces the unique advantages of nanodrug delivery systems in the treatment of hematological malignancies, focusing on the factors involved in tailoring nanoparticles and different types of nanomaterials. It reviews the recent advances in nanodrug delivery systems for HM treatment and discusses the challenges and prospects they face.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Oncology
Zhuoya Yu, Xiangxiang Zhou, Xin Wang
Summary: Metabolic reprogramming, a hallmark of cancer progression, supports tumorigenesis and tumor progression by allowing cells to uptake essential nutrients and altering metabolic pathways to meet increased demands for energy and biosynthetic precursors. Activated oncogenes coordinate with altered metabolism to control cell-autonomous pathways, potentially leading to tumorigenesis. Targeting metabolic features of hematologic malignancies has shown promising therapeutic potential in both clinical and preclinical studies.
Review
Oncology
Zheng Tian, Ming Liu, Ya Zhang, Xin Wang
Summary: Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies. Bispecific antibodies such as BiTEs have shown potential in recruiting T cells to tumor cells for immunotherapy, with a focus on improving efficacy and safety in clinical treatments for hematologic malignancies.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Hematology
Sarah El Iskandarani, Gary Deng
Summary: Acupuncture is an integrative medicine modality that has been widely used for managing various symptoms and diseases. There is evidence supporting the effectiveness of acupuncture in reducing common symptoms experienced by patients with hematological malignancies.
Article
Immunology
Zilong Guo, Yirui Zhang, Mingpeng Fu, Liang Zhao, Zhen Wang, Zhuoshuo Xu, Huifen Zhu, Xiaoli Lan, Guanxin Shen, Yong He, Ping Lei
Summary: The transferrin receptor (TfR) is being evaluated as an alternative target for CAR T cell therapy, showing potent cytotoxic effects against hematological malignancies. This suggests TfR could potentially broaden and enhance the therapeutic efficacy of CAR T cells, making it a promising universal target for further research.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Thomas Martin, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin, Sundar Jagannath
Summary: PURPOSECARTITUDE-1, a phase Ib/II study, evaluated the safety and efficacy of Ciltacabtagene Autoleucel in heavily treated patients with relapsed/refractory multiple myeloma. The study showed early, deep, and durable responses at 12 months, with updated results at 2 years. Patients received a single infusion of Ciltacabtagene Autoleucel and responses were assessed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Hematology
Adam D. Cohen, Maria-Victoria Mateos, Yael C. Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W. C. J. van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C. De Braganca, Christina Corsale, Jordan M. Schecter, Helen Varsos, William Deraedt, Liwei Wang, Martin Vogel, Tito Roccia, Xiaoying Xu, Pankaj Mistry, Enrique Zudaire, Muhammad Akram, Tonia Nesheiwat, Lida Pacaud, Irit Avivi, Jesus San-Miguel
Summary: The CARTITUDE-2 study evaluated the safety and efficacy of cilta-cel in patients with multiple myeloma who had previously received anti-BCMA treatment. The results showed that cilta-cel induced favorable responses in patients who had exhausted other therapies.
Article
Oncology
Adam D. Cohen, Parameswaran Hari, Myo Htut, Jesus G. Berdeja, Saad Z. Usmani, Deepu Madduri, Yunsi Olyslager, Jenna D. Goldberg, Jordan M. Schecter, Carolyn C. Jackson, Katharine S. Gries, John M. Fastenau, Satish Valluri, William Deraedt, Muhammad Akram, Rebecca Crawford, Ross Morrison, Lynda Doward, Kate Morgan, Silene ten Seldam, Andrzej Jakubowiak, Sundar Jagannath
Summary: Ciltacabtagene autoleucel (cilta-cel) is a CAR-T cell therapy that has shown efficacy in patients with relapsed/refractory multiple myeloma and improvements in health-related quality of life. Patient perspectives on cilta-cel treatment provide additional context to clinical outcomes and the majority of patients reported that their expectations were met or exceeded.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Marco Dicanio, Matteo Giaccherini, Alyssa Clay-Gilmour, Angelica Macauda, Juan Sainz, Mitchell J. Machiela, Malwina Rybicka-Ramos, Aaron D. Norman, Agata Tyczynska, Stephen J. Chanock, Torben Barington, Shaji K. Kumar, Parveen Bhatti, Wendy Cozen, Elizabeth E. Brown, Anna Suska, Eva K. Haastrup, Robert Z. Orlowski, Marek Dudzinski, Ramon Garcia-Sanz, Marcin Kruszewski, Joaquin Martinez-Lopez, Katia Beider, Elzbieta Iskierka-Jazdzewska, Matteo Pelosini, Sonja Berndt, Malgorzata Razny, Krzysztof Jamroziak, S. Vincent Rajkumar, Artur Jurczyszyn, Annette Juul Vangsted, Pilar Garrido Collado, Ulla Vogel, Jonathan N. Hofmann, Mario Petrini, Aleksandra Butrym, Susan L. Slager, Elad Ziv, Edyta Subocz, Graham G. Giles, Niels Frost Andersen, Grzegorz Mazur, Marzena Watek, Fabienne Lesueur, Michelle A. T. Hildebrandt, Daria Zawirska, Lene Hyldahl Ebbesen, Herlander Marques, Federica Gemignani, Charles Dumontet, Judit Varkonyi, Gabriele Buda, Arnon Nagler, Agnieszka Druzd-Sitek, Xifeng Wu, Katalin Kadar, Nicola J. Camp, Norbert Grzasko, Rosalie G. Waller, Celine Vachon, Federico Canzian, Daniele Campa
Summary: The aim of this study was to identify novel pleiotropic variants involved in multiple myeloma (MM) risk. Through analysis of 28,684 single nucleotide polymorphisms (SNPs), DNAJB4-rs34517439-A was found to be associated with an increased risk of developing MM.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Hematology
Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J. Schiller, Shira N. Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S. Wang, Karen P. Seiter, Andrew H. Wei, Stephane De Botton, Montserrat Arnan, Will Donnellan, Anthony P. Schwarer, Christian Recher, Brian A. Jonas, P. Brent Ferrell Jr, Christophe Marzac, Patrick Kelly, Jennifer Sweeney, Sanjeev Forsyth, Sylvie M. Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, Jorge E. Cortes
Summary: This study evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of Olutasidenib in patients with acute myeloid leukemia or myelodysplastic syndrome with mutant IDH1. The results showed that Olutasidenib, as monotherapy or in combination with azacitidine, was well tolerated and exhibited meaningful clinical activity. These findings provide a rationale for further evaluation of Olutasidenib in different populations of patients with myeloid malignancies.
LANCET HAEMATOLOGY
(2023)
Article
Biochemical Research Methods
Timothy R. Blake, Ole A. W. Haabeth, Adrienne Sallets, Rebecca L. McClellan, Trevor J. Del Castillo, Jose G. Vilches-Moure, Wilson C. Ho, Paul A. Wender, Ronald Levy, Robert M. Waymouth
Summary: Targeted delivery of nucleic acid therapeutics to the lungs shows promise for treating pulmonary diseases. New lysine-derived CART-mRNA complexes (K-CARTs/mRNA) demonstrate selective protein expression in the lungs without additives or targeting ligands. The ability to direct protein expression selectively in the spleen or lungs by simple changes to the CART structure opens new opportunities in research and gene therapy.
BIOCONJUGATE CHEMISTRY
(2023)
Article
Oncology
Nikhil Shri Sahajpal, Ashis K. Mondal, Harmanpreet Singh, Ashutosh Vashisht, Sudha Ananth, Daniel Saul, Alex R. Hastie, Benjamin Hilton, Barbara R. DuPont, Natasha M. Savage, Vamsi Kota, Alka Chaubey, Jorge E. Cortes, Ravindra Kolhe
Summary: The current genetic testing of myeloid cancers lacks resolution and is limited to specific genomic regions/genes. This study used a combination of high-resolution cytogenetic technology and next-generation sequencing to obtain a comprehensive genomic profile of these tumors. The combinatorial approach identified new genetic alterations and clinically relevant alterations in previously negative cases.
Article
Hematology
Oren Pasvolsky, Denai R. Milton, Adeel Masood, Sophiya S. Sami, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Arsalan Saeed, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash
Summary: The optimal duration of Len maintenance for MM patients after autoHCT is uncertain. A retrospective analysis was conducted on MM patients who underwent upfront autoHCT followed by single-agent Len maintenance between 2005 and 2021. The results showed that longer maintenance duration, even beyond 5 years, was associated with improved survival. However, longer maintenance duration was also linked to a higher risk of developing a second primary malignancy (SPM).
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schoenland, Ashutosh Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini
Summary: The VITAL trial assessed the efficacy and safety of birtamimab in combination with standard of care in AL amyloidosis patients. Although no significant difference was observed in the overall results, a post hoc analysis showed significant improvement in survival time at month 9 for Mayo stage IV patients treated with birtamimab.
Article
Hematology
Oren Pasvolsky, Curtis Marcoux, Denai R. Milton, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Priti Tewari, Lindsay Crawford-Suber, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash
Summary: This study analyzed the data of 117 young adults with multiple myeloma (MM) undergoing autologous transplantation and found that auto-HCT had a favorable outcome for them. Furthermore, the survival of younger MM patients improved with the availability of novel anti-myeloma drugs in recent years. Depth of response following transplant was a key predictor of survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Hematology
Marisol Miranda-Galvis, Kellen C. Tjioe, E. Andrew Balas, Gagan Agrawal, Jorge E. Cortes
Summary: This article evaluates the impact of social determinants of health on the outcomes of patients with hematologic malignancies. The study found that factors such as education level, health insurance coverage, income level, and marital status significantly affect patients' survival rates. However, there are contradictory reports regarding the effect of distance to treatment centers on treatment outcomes. Additionally, data on transportation, debt, diet, and other factors are lacking.
Article
Hematology
Ethan P. Damron, Muzaffar H. Qazilbash, Penny Q. Fang, Susan Y. Wu, Bouthaina S. Dabaja, Gabriela Rondon, Chitra Hosing, Richard E. Champlin, Qaiser Bashir, Elizabeth J. Shpall, Mark K. Knafl, Hans C. Lee, Elisabet E. Manasanch, Krina Patel, Sheeba K. Thomas, Robert Z. Orlowski, Donna M. Weber, Chelsea C. Pinnix, Jillian R. Gunther
Summary: The primary treatment of multiple myeloma (MM) often includes systemic induction therapy (SIT) and autologous stem cell transplantation (ASCT). However, radiation therapy (RT) is sometimes avoided due to concerns about its effect on peripheral blood progenitor cell (PBPC) collection for ASCT. This study retrospectively examined the possible impact of RT on PBPC collection in MM patients. The results showed that RT prior to ASCT did not impair the successful collection of PBPCs.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Meeting Abstract
Oncology
Ehab Atallah, Michael Mauro, Koji Sasaki, Moshe Levy, Paul Koller, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Aram Bidikian, Sreyashi Basu, Zhong He, Himachandana Atluri, Jabra Zarka, Michael Andreeff, Koji Sasaki, Elias Jabbour, Jorge E. Cortes, Padmanee Sharma, Ghayas C. Issa
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Joannie Clements, Cristina Ruiz, Andrea Damon, Peter Schuld, Pauline Frank, Cristina Constantinescu, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
